Our genes, our selves: hereditary breast cancer and biological citizenship in Norway
- 5 October 2016
- journal article
- research article
- Published by Springer Nature in Medicine, Health Care and Philosophy
- Vol. 20 (1) , 89-103
Abstract
In this paper we explore the rise of ‘the breast cancer gene’ as a field of medical, cultural and personal knowledge. We address its significance in the Norwegian public health care system in relation to so-called biological citizenship in this particular national context. One of our main findings is that, despite its claims as a measure for health and disease prevention, gaining access to medical knowledge of BRCA 1/2 breast cancer gene mutations can also produce severe instability in the individuals and families affected. That is, although gene testing provides modern subjects with an opportunity to foresee their biological destiny and thereby become patients in waiting, it undoubtedly also comes with difficult existential dilemmas and choices, with implications that resonate beyond the individual and into different family and love relations. By elaborating on this finding we address the question of whether the empowerment slogan, which continues to be advocated through various health, BRCA and breast cancer discourses, reinforces a naïve or an idealized notion of the actively responsible patient: resourceful enough to seek out medical expertise and gain sufficient knowledge, on which to base informed decisions, thereby reducing the future risk of developing disease. In contrast to this ideal, our Norwegian informants tell a different story, in which there is no apparent heroic mastery of genetic fates, but rather a pragmatic attitude to dealing with a dire situation over which they have little control, despite having complied with medical advice through national guidelines and follow-up procedures for BRCA 1/2 carriers. In conclusion we claim that the sense of safety that gene testing and its associated medical solutions allegedly promise to provide proved illusory. Although BRCA-testing offers the potential for protection from adverse DNA-heritage, administered through possibilities for self-monitoring and self-management of the body, the feeling of ‘being in good health’ has hardly been reinforced by the emergence of gene technology.Keywords
Funding Information
- Folke Hermansen Cancer Research Foundation
- Inge Steensland Foundation
This publication has 33 references indexed in Scilit:
- Contralateral risk-reducing mastectomy in sporadic breast cancerThe Lancet Oncology, 2013
- Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance programBreast Cancer Research and Treatment, 2013
- Breast cancer after bilateral risk-reducing mastectomyClinical Genetics, 2011
- Prophylactic mastectomy for the prevention of breast cancerCochrane Database of Systematic Reviews, 2010
- High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective seriesHereditary Cancer in Clinical Practice, 2010
- Types of social capital resources and self-rated health among the Norwegian adult populationInternational Journal for Equity in Health, 2010
- Survival in Norwegian BRCA1 mutation carriers with breast cancerHereditary Cancer in Clinical Practice, 2009
- Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriersEuropean Journal of Cancer, 2007
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- How sociology can save bioethics . . . maybeSociology of Health & Illness, 2004